330 related articles for article (PubMed ID: 20570112)
21. Myeloid-derived suppressor cells in human cancer.
Nagaraj S; Gabrilovich DI
Cancer J; 2010; 16(4):348-53. PubMed ID: 20693846
[TBL] [Abstract][Full Text] [Related]
22. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells.
Tian J; Ma J; Ma K; Guo H; Baidoo SE; Zhang Y; Yan J; Lu L; Xu H; Wang S
Eur J Immunol; 2013 May; 43(5):1220-30. PubMed ID: 23424024
[TBL] [Abstract][Full Text] [Related]
23. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts.
Maenhout SK; Van Lint S; Emeagi PU; Thielemans K; Aerts JL
Int J Cancer; 2014 Mar; 134(5):1077-90. PubMed ID: 23983191
[TBL] [Abstract][Full Text] [Related]
24. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
Lizée G; Radvanyi LG; Overwijk WW; Hwu P
Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
[TBL] [Abstract][Full Text] [Related]
25. Transcription factors in myeloid-derived suppressor cell recruitment and function.
Sonda N; Chioda M; Zilio S; Simonato F; Bronte V
Curr Opin Immunol; 2011 Apr; 23(2):279-85. PubMed ID: 21227670
[TBL] [Abstract][Full Text] [Related]
26. Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice.
Chu M; Su YX; Wang L; Zhang TH; Liang YJ; Liang LZ; Liao GQ
Oral Dis; 2012 Jan; 18(1):67-73. PubMed ID: 21883708
[TBL] [Abstract][Full Text] [Related]
27. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
28. Myeloid-derived suppressor cells in cancer: recent progress and prospects.
Khaled YS; Ammori BJ; Elkord E
Immunol Cell Biol; 2013 Sep; 91(8):493-502. PubMed ID: 23797066
[TBL] [Abstract][Full Text] [Related]
29. Insights into Myeloid-Derived Suppressor Cells in Inflammatory Diseases.
Kwak Y; Kim HE; Park SG
Arch Immunol Ther Exp (Warsz); 2015 Aug; 63(4):269-85. PubMed ID: 25990434
[TBL] [Abstract][Full Text] [Related]
30. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
Seliger B; Massa C; Rini B; Ko J; Finke J
Trends Mol Med; 2010 Apr; 16(4):184-92. PubMed ID: 20304705
[TBL] [Abstract][Full Text] [Related]
31. The roles of myeloid-derived suppressor cells in transplantation.
Wu T; Zhao Y; Zhao Y
Expert Rev Clin Immunol; 2014 Oct; 10(10):1385-94. PubMed ID: 25119260
[TBL] [Abstract][Full Text] [Related]
32. A copper chelate selectively triggers apoptosis in myeloid-derived suppressor cells in a drug-resistant tumor model and enhances antitumor immune response.
Chakraborty P; Das S; Banerjee K; Sinha A; Roy S; Chatterjee M; Choudhuri SK
Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):165-75. PubMed ID: 24611750
[TBL] [Abstract][Full Text] [Related]
33. Immune responses in hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Dig Dis; 2010; 28(1):150-4. PubMed ID: 20460904
[TBL] [Abstract][Full Text] [Related]
34. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
Yang R; Cai Z; Zhang Y; Yutzy WH; Roby KF; Roden RB
Cancer Res; 2006 Jul; 66(13):6807-15. PubMed ID: 16818658
[TBL] [Abstract][Full Text] [Related]
35. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
Talmadge JE
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5243-8. PubMed ID: 17875751
[TBL] [Abstract][Full Text] [Related]
36. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
Sinha P; Clements VK; Ostrand-Rosenberg S
Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
[TBL] [Abstract][Full Text] [Related]
39. Myeloid cell population dynamics in healthy and tumor-bearing mice.
Ueha S; Shand FH; Matsushima K
Int Immunopharmacol; 2011 Jul; 11(7):783-8. PubMed ID: 21406269
[TBL] [Abstract][Full Text] [Related]
40. Myeloid-derived suppressor cells: paradoxical roles in infection and immunity.
Dai J; El Gazzar M; Li GY; Moorman JP; Yao ZQ
J Innate Immun; 2015; 7(2):116-26. PubMed ID: 25401944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
